1Q 2009 Results Presentation. 12 May 2009

Size: px
Start display at page:

Download "1Q 2009 Results Presentation. 12 May 2009"

Transcription

1 1Q 2009 Results Presentation 12 May

2 Broadcasting 2

3 MEDIASET Q Total Audience TOTAL AUDIENCE (Jan-Mar) * Individuals Δ vs % years +5.6% 1Q TV CONSUMPTION ( ) Average Daily minutes (Individuals) * Average daily audience Broadcasting 3

4 MEDIASET Q Audience Share 24 Hours Prime Time ( ) INDIVIDUALS 40.2% 40.2% 41.5% 40.8% COMMERCIAL TARGET (15-64 Years) 35.4% 42.8% 38.3% 42.9% Source: Auditel excl. SanRemo (11/01 31/03) Broadcasting 4

5 MEDIASET Q Audience Trend grew both in Prime Time and Day Time Prime Time INDIVIDUALS Δ vs. 1Q2008 COMMERCIAL TARGET Δ vs. 1Q Day Time Source: Auditel excl. SanRemo (Jan-Mar 2009 vs 2008) Broadcasting 5

6 MEDIASET Q Audience Share (15-64 years) Day Time CANALE 5 Objective* 23.0% Audience** 23.8% ITALIA % 11.8% RETE 4 7.0% 7.2% Prime Time MEDIASET CANALE % 24.0% 42.8% 25.3% ITALIA % 11.1% RETE 4 7.0% 6.6% Source: Auditel excl. SanRemo * The objective period goes from 11/01 to 30/05 ** The actual audience period goes from 11/01 to 31/03 MEDIASET 43.0% 43.0% Broadcasting 6

7 Advertising 7

8 Italian Advertising Market Snapshot Jan\Feb 2009 vs Mediaset Total Market without Mediaset Rai Newspapers* Magazines Radio -13.9% -22.1% -23.1% -33.9% -29.6% -27.2% Source: Nielsen (February) * Commercial National Newspaper Advertising 8

9 MEDIASET Q Publitalia Advertising Revenues -13.0% (Euro ml.) 1Q Q 2009 Advertising 9

10 MEDIASET Q Top Investors (1Q2009 vs. 1Q2008) TOP 10 * TOP 20 * -8.3% -9.0% * Top 2008 clients for Publitalia (sales order) Advertising 10

11 MEDIASET Q Advertising Breakdown by Sector vs. 1Q 2008 MEDIA/PUBLISHING FOOD NON FOOD -24.3% -16.5% -14.4% Advertising 11

12 MEDIASET Q Advertising Breakdown by Sector vs. 1Q 2008 TELECOM AUTOMOTIVE FINANCE/INSURANCE -4.9% -5.8% -10.6% Advertising 12

13 MEDIASET Q Advertising Breakdown by Sector vs. 1Q 2008 RETAIL PHARMACEUTICAL/HEALTH +25.5% +4.5% Advertising 13

14 Financials 14

15 MEDIASET GROUP Q P&L Highlights (Euro ml.) 1Q Q 2009 Net Consolidated Revenues 1, EBITDA EBIT NET PROFIT (Reported) NET PROFIT (Adjusted*) *Excluding the net impact of the amortisation of intangibles related to the PPA of Endemol Financials 15

16 Financials Italian Business 16

17 MEDIASET ITALIAN BUSINESS Q P&L Results (Euro ml.) 1Q Q 2009 Net Consolidated Revenues Personnel Costs Other Operating Costs EBITDA Rights Amortisation Other Amortisation & Depreciation Operating Profit Financial Income (Losses) Associates Pre-Tax Profit Taxes NET PROFIT (107.1) (351.2) (225.1) (29.2) (17.2) (40.1) (111.1) (349.1) (218.8) (33.1) 95.6 (14.5) (31.2) 47.4 Financials 17

18 MEDIASET ITALIAN BUSINESS Q Operations Breakdown (Euro ml.) Total Net Revenues Total Costs (including D&A) Operating Profit FTA TV (480.4) 94.3 Network Operator 58.8 (46.0) 12.8 Pay TV (152.9) (14.0) Other Activities (104.0) 18.8 Intra-company Eliminations (31.5) Adjustments (56.0) 39.7 (16.3) TOTAL Financials 18

19 MEDIASET ITALIAN BUSINESS Q FTA TV Operations (Euro ml.) Total Net TV Revenues TV Advertising Revenues Multichannel Adv. Revenues Commissions Other TV Revenues Total TV Costs Personnel TV Operating Costs TV Rights Amortisations Other A&D Net Intra-company Items FTA TV Operating Profit margin 1Q (110.5) 16.6 (489.1) (88.4) (222.7) (149.6) (11.2) (17.3) % 1Q (96.1) 23.2 (480.4) (89.9) (212.3) (150.4) (13.9) (13.9) % Financials 19

20 MEDIASET ITALIAN BUSINESS Q Network Operator (Euro ml.) Total Net Revenues 3 Party DVB-T/DVB-H Revenues Other Revenues Net intra-company Items Total Costs Personnel Other Operating Costs Other Amortisation & Depreciation Network Operator Operating Profit margin 1Q (47.9) (8.8) (23.7) (15.4) % 1Q (46.0) (9.2) (23.7) (13.1) % Financials 20

21 MEDIASET PREMIUM 2 New Hits in Premium Gallery bouquet 1 year ago Today +1 Financials 21

22 MEDIASET PREMIUM Active Clients 3,275,000 3,361,000 2,911, Season 2,067,000 2,506,000 2,567, Season Jul 31 Dec 31 Mar 30 Apr Source: Company data, until 30 April 2009 Financials 22

23 MEDIASET ITALIAN BUSINESS Q Pay TV (Euro ml.) Total Net Pay TV Revenues Pay TV Revenues Advertising Revenues Other Revenues Commissions Total Pay TV Costs Personnel Other Operating Costs Rights Amortisations and Other D&A Net intra-company items Pay TV Operating Profit 1Q (0.4) (137.8) (1.1) (53.3) (72.2) (11.2) (29.0) 1Q (1.0) (152.9) (3.1) (63.6) (69.9) (16.4) (14.0) Financials 23

24 MEDIASET ITALIAN BUSINESS Q Other Activities (Euro ml.) Total Net Revenues Medusa/Taodue 3 Party revenues Medusa/Taodue intra-company revenues Multimedia Mediashopping Other Non-TV Revenues Total Costs Personnel Other Operating Cost Right Amortisations Other Amortisations & Depreciations Intra-company Items Other Activities Operating Profit margin 1Q (93.6) (8.8) (52.0) (28.6) (2.3) (1.9) % 1Q (104.0) (8.9) (57.9) (32.1) (3.8) (1.3) % Financials 24

25 MEDIASET ITALIAN BUSINESS Q Investments 1Q Q 2009 (Euro ml.) TV rights and cinema Pay TV rights DTT Technical & immaterial Option rights Total Investments Financials 25

26 MEDIASET ITALIAN BUSINESS Q Cash Flow Statement (Euro ml.) 1Q Q 2009 Initial Net Financial Position (01/01) Cash Flow from Operations Investments Disinvestments Change in Net Working Capital (CNWC) Free Cash Flow Change in consolidation area Equity (Investments)/Disinvestment Change in Equity Total Net Cash Flow Final Net Financial Position (31/03) Consolidated Net Financial Position (31/03) (1,222.0) (627.5) (13.7) (1,066.9) (967.3) (1,345.8) (237.5) 0.7 (1.6) (1.4) (1,280.7) (1,256.3) Financials 26

27 MEDIASET SPANISH BUSINESS Back up Slides 27

28 TELECINCO Q P&L Results (Euro ml.) 1Q Q 2009 Net Consolidated Revenues Personnel Costs Other Operating Costs EBITDA Amortisation & Depreciation EBIT Financial Income (Losses) Associates Pre-Tax Profit Taxes NET PROFIT Reported NET PROFIT Adjusted* (20.8) (75.5) (34.8) (8.3) (29.7) (20.4) (53.0) 86.2 (42.5) (11.6) 32.1 (5.2) *Excluding the net impact of the amortisation of intangibles related to the PPA of Endemol Financials 28

29 TELECINCO Q Investments (Euro ml.) 1Q Q 2009 TV rights Co-production & Distribution Tangible & Intangible Fixed Assets Total 57.1 Investments Financials 29

30 TELECINCO Q Cash Flow Statement (Euro ml.) 1Q Q 2009 Initial Net Financial Position (01/01) Free Cash Flow Cash Flow from Operations Investments Change in Net Working Capital (CNWC) Change in Equity Equity (Investments)/Disinvest. Cashed in Dividends Treasury Shares Total Net Cash Flow Final Net Financial Position (31/03) (54.1) (23.2) (25.9) (57.1) 33.6 (2.6) (2.9) Financials 30

31 Investor Relations Department: Tel: Fax: WebSite: Forward-looking Statements Statements contained in this document, particularly the ones regarding any Mediaset Group possible or assumed future performance, are or may be forward looking statements and in this respect they involve some risks and uncertainties. Mediaset Group actual results and developments may differ materially from the ones expressed or implied by the above statements depending on a variety of factors. Any reference to past performance of Mediaset Group shall not be taken as an indication of future performance. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein. The executive responsible for the preparation of the Mediaset S.p.A. accounts, Andrea Goretti, declares that, as per para. 2 art. 154-bis, of the Testo Unico della Finanza, that the accounting information contained in this document corresponds to that contained in the company s books. 31

2010 First Quarter Results Presentation. 11 th May 2010

2010 First Quarter Results Presentation. 11 th May 2010 2010 First Quarter Results Presentation 11 th May 2010 1 Broadcasting 2 ITALY TV Consumption trend (2003-2010) Average Daily minutes 271 273 270 270 Individuals 269 266 255 250 251 245 251 256 245 244

More information

M e d i a s e t G r o u p

M e d i a s e t G r o u p M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%

More information

MARCH 2014 RESULTS PRESENTATION Madrid, 2014

MARCH 2014 RESULTS PRESENTATION Madrid, 2014 MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted

More information

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

Endesa 1Q 2017 Results 09/05/2017

Endesa 1Q 2017 Results 09/05/2017 Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures

More information

ELICA 2012 Q3 RESULTS. November 14,

ELICA 2012 Q3 RESULTS. November 14, ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation

More information

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1- BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

FY2016 1H Results. Cookpad Inc.

FY2016 1H Results. Cookpad Inc. FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

Summary Statement of Financial Position (consolidated)

Summary Statement of Financial Position (consolidated) 2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,

More information

Welcome to LG Electronics

Welcome to LG Electronics Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015

PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015 PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015 KEY MESSAGES AGENDA 1Q 2015 RESULTS 2015 OUTLOOK & TARGETS 1Q 2015 TYRE OVERVIEW APPENDIX 1Q 2015 RESULTS 1 KEY MESSAGES > A solid 1Q 2015 with Premium outperformance

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Korean Airlines Q Results

Korean Airlines Q Results Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and

More information

Results Briefing Junichi Yoshii President & Representative Director

Results Briefing Junichi Yoshii President & Representative Director Fiscal Year Ending March 2010 Results Briefing Junichi Yoshii President & Representative Director May 14, 2010 1 Overview of Results (Consolidated) (Million yen) Net sales Operating profit Recurring income

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Woongjin Coway. 1Q 12 IR Presentation

Woongjin Coway. 1Q 12 IR Presentation Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007 Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

Third-quarter results 2013

Third-quarter results 2013 Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen

More information

PVD (PVDrilling) Company Visit October 2011

PVD (PVDrilling) Company Visit October 2011 PVD (PVDrilling) Company Visit October 2011 2011 Preview: 3Q11 EBT margin is expected to be higher than 2Q11 largely due to no booking of provision for Science and Technology Development Fund According

More information

For personal use only

For personal use only Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

THIRD QUARTER REPORT 2011 (UNAUDITED)

THIRD QUARTER REPORT 2011 (UNAUDITED) THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor

More information

Total Face Group Limited

Total Face Group Limited Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position

More information

Q2 INVESTOR KIT JANUARY-JUNE 2011

Q2 INVESTOR KIT JANUARY-JUNE 2011 Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

Group financial results for the first quarter 2008

Group financial results for the first quarter 2008 Helmut Perlet, Member of the Board of Management Group financial results for the first quarter 2008 Journalists Conference Call May 9th, 2008 Group: robust earnings in stormy weather (EUR mn) Quarterly

More information

Results Briefing. 15 ~ 17 May 2007

Results Briefing. 15 ~ 17 May 2007 Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights

More information

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland

More information

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION

More information

Q Investor Kit January December 2015

Q Investor Kit January December 2015 Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local

More information

DELICA D:5 ACTIVE GEAR 0

DELICA D:5 ACTIVE GEAR 0 DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

1Q2005. Hera Group presentation

1Q2005. Hera Group presentation 1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients

More information

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO

FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

May 6, 2008 First Quarter 2008 Results

May 6, 2008 First Quarter 2008 Results SWEUB2227319CMDV7 May 6, 28 First Quarter 28 Results 1Q 28: Improved results in a challenging environment Page 2 Strong loan growth at 34.2% yoy Accelerated deposit growth at 31% yoy; improved loans /

More information

WntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE

WntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should

More information

Presentation of. Burgdorf, 1 st November 2012

Presentation of. Burgdorf, 1 st November 2012 Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,

More information

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS

PRESENTATION ON 2017 THIRD QUARTERLY RESULTS Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness

More information

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109

More information

METVIX PDT ON THE MARKET IN GERMANY AND UK

METVIX PDT ON THE MARKET IN GERMANY AND UK METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone

More information

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total

More information

1Q 2015 Results A Positive Start to 2015

1Q 2015 Results A Positive Start to 2015 1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results

More information

Sirtex Medical Ltd Buy

Sirtex Medical Ltd Buy Research Sirtex Medical Ltd Buy Price: A$16.32 Price Target: A$20.50 ASX: SRX 21 April 2017 Sirtex Medical (SRX) is a global medical device company which targets cancer therapies, with its lead product

More information

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009

FY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009 FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)

More information

Review of Half Year 2010

Review of Half Year 2010 Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming

More information

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive

More information

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth

More information

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology

More information

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183) Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

1Q 2014 Earnings Release

1Q 2014 Earnings Release 1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains

More information

Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK

Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set

More information

Group 1Q FY13 financial highlights

Group 1Q FY13 financial highlights Singapore Press Holdings 1Q FY13 Financial Results 14 January 2013 Group 1Q FY13 financial highlights 1Q FY13 S$ 000 1Q FY12 S$ 000 Change % Operating Revenue 322,092 332,406 (3.1) Operating Profit # 109,371

More information

ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011

ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK. Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 ARUBA RECENT ECONOMIC DEVELOPMENTS AND OUTLOOK Presented by Jane R. Semeleer President Centrale Bank van Aruba May 30, 2011 STRUCTURE 1. National economy 2. International economy 3. Outlook 2 CENTRALE

More information

WntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE

WntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE Occasion: Company announcements +32% +58% Pearls on a string has had troublesome times, but now everything seems to fall into place. With a new CEO in charge the phase II trials close to commencing in

More information

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase

More information

Friends raises funds, offers expertise, collects donations, and provides volunteer support to help:

Friends raises funds, offers expertise, collects donations, and provides volunteer support to help: ANNUAL REPORT 2015 1603 22 nd Street Anacortes, WA 98221 Phone: 360-293-0673 Ext. 106 FAX: 360-299-2953 Website: fidalgopool.com Friends of Fidalgo Pool and Fitness Center is a 501(c)(3) nonprofit charitable

More information

Leading Intimate Healthcare

Leading Intimate Healthcare 21 May 2008 1 Leading Intimate Healthcare Investor presentation H1 2007/08 2 Agenda Introduction to Coloplast First 6 months 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate

More information

Consolidated: Financial Summary

Consolidated: Financial Summary FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

Investor Presentation

Investor Presentation Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of

More information

Passion for progress, care for people

Passion for progress, care for people Passion for progress, care for people SPIL Analyst Meeting 25 th April, 2008 DISCLAIMER ACTUAL RESULTS / OUTCOMES MAY BE DIFFERENT FROM ANY FORWARD LOOKING STATEMENTS / VIEWS / ESTIMATES EXPRESSED HEREIN.

More information

Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses

More information

Coloplast A/S. Investor Presentation 2005/06

Coloplast A/S. Investor Presentation 2005/06 Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

Interim Report 1 January September 2017

Interim Report 1 January September 2017 2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights

More information

Interim report Second quarter 2017 and subsequent events (Unaudited)

Interim report Second quarter 2017 and subsequent events (Unaudited) SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities

More information

22nd Century Group, Inc. (XXII - $ Buy)

22nd Century Group, Inc. (XXII - $ Buy) Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor

More information

Cowen Healthcare Conference

Cowen Healthcare Conference Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

Rovi. First Quarter 2018 Financial Results

Rovi. First Quarter 2018 Financial Results Rovi First Quarter 218 Financial Results Disclaimer This document has been prepared by Laboratorios Farmacéuticos Rovi, S.A. ( ROVI or the Company ), solely for its use during the attached presentation.

More information

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

Corporate Presentation 1Q18. New growth cycle and value innovation

Corporate Presentation 1Q18. New growth cycle and value innovation Corporate Presentation 1Q18 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Sustainability 4 Strategic competitive advantages 5 Financial

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

INVESTOR PRESENTATION SEPTEMBER 2017

INVESTOR PRESENTATION SEPTEMBER 2017 INVESTOR PRESENTATION SEPTEMBER 2017 DABUR OVERVIEW One of the oldest and largest FMCG Companies in the country World s largest in Ayurveda and natural healthcare Total reach of 6 mn outlets, one of the

More information

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011 H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts

More information

ONO PHARMACEUTICAL CO., LTD.

ONO PHARMACEUTICAL CO., LTD. ONO PHARMACEUTICAL CO., LTD. February 4, 2005 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2005

More information

Investor Update May 2016

Investor Update May 2016 Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico

More information

Immunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007

Immunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007 Immunity for Life TM Third Quarter 2007 CEO Lars Viksmoen CFO Finn Samuelsen 31 October 2007 Operational Highlights for Q3 2007 Clinical phase III study with SBG for treatment of diabetic ulcers; enrolment

More information

SUMMARY TERM SHEET. Sl. Particulars Details 1. Issuer L&T Finance Holdings Limited (the Company / the Issuer / L&TFHL )

SUMMARY TERM SHEET. Sl. Particulars Details 1. Issuer L&T Finance Holdings Limited (the Company / the Issuer / L&TFHL ) SUMMARY TERM SHEET Sl. Particulars Details 1. Issuer L&T Finance Holdings Limited (the Company / the Issuer / L&TFHL ) 2. Date of resolution May 28, 2014 passed by the Board of Directors authorizing the

More information